Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS NM STI Diagnostic Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - New MexicoPolicy RPLAB051

    Diagnostic Testing of Common Sexually Transmitted Infections

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB051 alerts

    Get alerted when Policy RPLAB051 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy governs coverage and reimbursement criteria for diagnostic testing of common STIs (C. trachomatis, N. gonorrhoeae, T. pallidum, T. vaginalis and select others) for Blue Cross Blue Shield of New Mexico providers and members.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyDiagnostic Testing of Common Sexually Transmitted Infections
    Policy CodePolicy RPLAB051
    Change TypeMaterial revisions and code updates (coverage moved from CPCPLAB014exclusions clarified)
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and valid code combinations; claims may require additional documentation upon request.
    SourceLink
    POLICY UPDATE CHANGES

    Added prenatal STI screening previously addressed on CPCPLAB014 Prenatal Testing (Non genetic), resulting in addition of #2.a, #5.e, #6.a, and #10.a.

    For individuals currently or previously diagnosed with syphilis, treponemal Ig testing is not reimbursable.

    For symptomatic individuals, testing for Mycoplasma genitalium using NAAT may be reimbursable; for asymptomatic individuals screening for M. genitalium using NAAT is not reimbursable.

    Trichomonas vaginalis added to #24 as not reimbursable (direct probe/quantitative NAAT section); added specific CPT/other codes.

    Qualitative NAAT phrasing added to several items for clarity (e.g., #4, #7, #12, #15).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1coverage moved in from CPCPLAB014
    2specific exclusions (treponemal Ig, syphilis PCR/NAAT/antigen)
    1clinical limitation: M. genitalium NAAT reimbursable when symptomatic
    23numbered reimbursement rules listed
    ~70unique procedure codes listed (approx.)

    Coverage and Reimbursement Criteria

    Reimbursement stance and criteria

    The policy specifies which diagnostic STI tests the Plan will reimburse and enumerates method- and indication-based exclusions. Reimbursable status depends on the test method, organism, and clinical circumstance.

    • Procedure and proprietary codes listed in the policy identify tests commonly used for syphilis, chlamydia, gonorrhea, HSV, HPV, trichomonas, M. genitalium and multi-agent NAAT panels; see procedure code inventory for specific CPT/HCPCS/U-codes.
    • Qualitative NAAT terminology was added for clarity and applies to coverage of many organism-specific NAATs (policy revisions noted).
    • Policy moved prenatal STI screening into this document from CPCPLAB014; corresponding prenatal screening rules are now reimbursable as specified (e.g., chlamydia/gonorrhea NAAT and syphilis antibody at first prenatal visit for eligible ages).
    • The policy explicitly adds and removes procedure codes over time; providers should reference the current code list when billing. Recent code additions and removals are recorded in policy history.
    • Certain test methods are explicitly not reimbursable across organisms: PCR/NAAT/antigen testing for syphilis; culture/antibody/antigen testing for chlamydia or LGV; direct probe detection and/or quantitative NAAT for listed organisms; rapid enzyme immunoassay for Trichomonas; nucleic acid antimicrobial susceptibility/resistance testing for N. gonorrhoeae or M. genitalium.

    Diagnosis of symptomatic infection for listed STIs

    NAATs, antibody, culture, and other methods may be reimbursable for diagnosis of symptomatic infection when organism-specific criteria are met.

    Diagnosis of symptomatic infection

    • Syphilis: Antibody testing (treponemal and nontreponemal) reimbursable for persons presenting with signs/symptoms of syphilis.
    • Chlamydia: Qualitative NAAT reimbursable for symptomatic individuals presenting with signs of chlamydial infection.
    • Gonorrhea: Qualitative NAAT reimbursable for symptomatic individuals presenting with signs of gonococcal infection; culture for antimicrobial susceptibility reimbursable when treatment failure is suspected.
    • Trichomonas: Qualitative NAAT reimbursable for symptomatic individuals; rapid enzyme immunoassay not reimbursable.
    • Mycoplasma genitalium: NAAT testing may be reimbursable for symptomatic individuals; asymptomatic screening is not reimbursable.

    Screening of asymptomatic individuals in defined high-risk groups

    Screening of asymptomatic individuals is covered only for defined high-risk groups and per specified frequency intervals.

    Screening criteria for asymptomatic high-risk groups

    • Syphilis antibody screening reimbursable once per year for asymptomatic persons in a high-risk category.once per year
    • Chlamydia qualitative NAAT reimbursable once per year for asymptomatic persons in a high-risk category; limited reimbursable screening for asymptomatic individuals not in high-risk groups (e.g., prenatal first visit for pregnant ≤24, newborn screening, sexual assault follow-up, sexually active <18 annually).once per year (high-risk)
    • Gonorrhea qualitative NAAT reimbursable once per year for asymptomatic persons in a high-risk category; similar limited exceptions for asymptomatic not high-risk (prenatal, newborn, assault follow-up, sexually active <18 annually).once per year (high-risk)

    Diagnostic testing for suspected or surveillance of sexually transmitted infections

    Diagnostic testing and surveillance for suspected STIs are reimbursable when they align with organism- and method-specific rules described elsewhere in this policy.

    Examples of diagnostic testing and surveillance indications

    • Syphilis: Treponemal and nontreponemal serology for diagnosis, staging, and test-of-cure as indicated (see timing rules and exclusions).
    • Chlamydia: Qualitative NAATs for diagnosis, suspected LGV, and test-of-cure per timing rules; culture/antigen/antibody methods not reimbursable.
    • Gonorrhea: Qualitative NAATs for diagnosis and test-of-cure per timing rules; culture for antimicrobial susceptibility reimbursable for suspected treatment failure.
    • Trichomonas: Qualitative NAAT for diagnosis and follow-up testing (minimum 3 months post-diagnosis); rapid enzyme immunoassay not reimbursable.

    Covered Indications and Organism-Specific Rules

    Mycoplasma genitalium NAAT testing

    Mycoplasma genitalium NAAT testing is limited to symptomatic diagnostic use; screening of asymptomatic persons is excluded.

    M. genitalium NAAT testing

    • NAAT testing for Mycoplasma genitalium may be reimbursable for symptomatic individuals when clinical signs/symptoms consistent with M. genitalium infection are present.
    • Screening or NAAT testing for M. genitalium in asymptomatic individuals is NOT reimbursable.
    • Nucleic acid testing to determine macrolide resistance in M. genitalium is NOT reimbursable.

    PrEP-related STI screening

    When providing or ordering PrEP-related STI screening, follow the frequency and test-type guidance below.

    Procedure Codes and Coding References

    Representative procedure codes listed in policymixed
    86592SYPHILIS TEST NON-TREP QUAL.
    86631CHLAMYDIA ANTIBODY.
    87494CHLMY TRCH&NEISRA GONOR MULT.
    87563M. GENITALIUM AMP PROBE.
    87661TRICHOMONAS VAGINALIS AMPLIF.
    0064UANTB TP TOTAL&RPR IA QUAL.
    0484UNFCT DS MGEN 23S RRNA PT MUT.
    Representative procedure codes listed in policy (alternate format)mixed
    No codes listed
    Selected covered procedure codesmixedCovered
    86592SYPHILIS TEST NON-TREP QUAL.
    86593SYPHILIS TEST NON-TREP QUANT.
    86631CHLAMYDIA ANTIBODY.
    86632CHLAMYDIA IGM ANTIBODY.
    86694HERPES SIMPLEX NES ANTBDY.
    86695HERPES SIMPLEX TYPE 1 TEST.
    86696HERPES SIMPLEX TYPE 2 TEST.
    86780TREPONEMA PALLIDUM.
    87491CHLMYD TRACH DNA AMP PROBE.
    87492CHLMYD TRACH DNA QUANT.
    1–10 of 21
    1/3
    Selected covered procedure codes (empty supplemental group)mixed
    No codes listed
    Codes added in policy historymixed
    87140CULTURE TYPE IMMUNOFLUORESC.
    87270CHLAMYDIA TRACHOMATIS AG IF.
    87285TREPONEMA PALLIDUM AG IF.
    87320CHLMYD TRACH AG IA.
    87660TRICHOMONAS VAGIN DIR PROBE.
    87810CHLMYD TRACH ASSAY W/OPTIC.
    87494CHLMY TRCH&NEISRA GONOR MULT.
    87626HPV SEP HI-RSK TYP&POOL RSLT
    87563M. GENITALIUM AMP PROBE.
    0402UONC URTHL MRNA XPRSN 6 SNP.
    1–10 of 14
    1/2
    Codes added in history (alternate)mixed
    No codes listed
    inv-07: Screening frequency examples
    Annual screening (asymptomatic high-risk)Once per year assessment for asymptomatic persons in high-risk categories (e.g., syphilis, chlamydia, gonorrhea, trichomonas as specified).
    Quarterly screening (MSM/HIV-positive MSM on PrEP)Once every three months for HIV-positive men or men who have sex with men (MSM) for syphilis; PrEP guidance also recommends every 3 months for NAAT gonorrhea/chlamydia screening for MSM.
    Semiannual screening (sexually active individuals on PrEP)Once every six months for sexually active individuals on PrEP for NAAT gonorrhea/chlamydia screening and syphilis blood testing.
    inv-08: CPT/HCPCS citation year
    CPT citation yearCPT copyright 2025 (American Medical Association).

    Screening Frequency and Follow-up Limits

    inv-23: Syphilis antibody screening for asymptomatic high-risk individuals
    FrequencyOnce per year for asymptomatic individuals in a high-risk category.
    Testing algorithmReimbursable using either a standard or reverse algorithm that includes initial and confirmatory tests (e.g., treponemal Ig test AND nontreponemal test).
    ExceptionsPregnant individuals and newborn screening have separate listed provisions; treponemal Ig testing is not reimbursable for those with current or past syphilis.
    inv-24: Syphilis blood testing and NAATs for MSM on PrEP or HIV-positive MSM per guidance
    Frequency for MSM on PrEP or HIV-positive MSMOnce every three months for syphilis blood testing and applicable NAATs per guidance.
    Context

    Tests and Methods Not Reimbursable

    This policy identifies several test methods that are not reimbursable. Specifically, PCR, NAAT, and antigen testing for syphilis are excluded from reimbursement (see item 4). Additionally, culture, antibody, and antigen testing for Chlamydia trachomatis or lymphogranuloma venereum (LGV) are not reimbursable (see items 5 and 7). For Trichomonas vaginalis, rapid enzyme immunoassay (rapid EIA) is explicitly listed as not reimbursable (see item 12). The policy also excludes direct probe detection and/or quantitative NAAT methods for a list of organisms including C. trachomatis, N. gonorrhoeae, HSV-1, HSV-2, T. pallidum, and T. vaginalis (see item 24).

    Within the procedure-code listings portion of the policy, there are no additional explicit test-method exclusions beyond the not-reimbursable methods described elsewhere; this section primarily catalogs CPT/HCPCS and proprietary codes for STI-related assays and does not itself list separate exclusions (see Procedure Codes listings).

    The policy was revised to add explicit exclusions related to syphilis testing: for individuals with a current or past syphilis infection, treponemal Ig testing is not reimbursable, and separately, PCR, NAAT, and antigen testing for syphilis are not reimbursable (see Policy History and item 4). These changes are recorded in the policy history and are operative in the reimbursement rules.

    Provider Documentation, Billing, and Ordering Requirements

    Documentation Required

    Documentation, coding and claims review

    Providers must submit accurate documentation of services performed and code claims using valid code combinations from HIPAA-approved code sets and standard coding guidance. Claims are subject to code edit protocols and may require additional documentation; the provider is urged to submit any requested supporting documentation upon claim review.

    Billing Rule

    Procedure code selection for STI tests (examples)

    Use the procedure codes listed in the policy when billing STI diagnostics; examples include codes for syphilis, chlamydia, herpes, HPV, gonorrhea, trichomonas, Mycoplasma genitalium, and multi-organism NAAT panels.

    • Syphilis: 86592, 86593, 86780

    Definitions and Testing Terminology

    inv-13: Syphilis antibody testing algorithm
    Syphilis algorithm optionsReimbursable testing may use either a 'standard' or 'reverse' algorithm (initial plus confirmatory testing such as treponemal Ig test AND nontreponemal test).
    Use casesApplicable for once-a-year screening of asymptomatic high-risk individuals and for diagnostic evaluation of symptomatic persons.
    Pre-transplant useTreponemal and nontreponemal testing once prior to allogeneic hematopoietic stem cell transplant for donors and recipients is reimbursable.
    inv-14: Qualitative NAAT — definition and intended use (detection not quantification)
    DefinitionQualitative NAAT refers to nucleic acid amplification tests intended for detection (not quantification) used for diagnosis or screening per listed indications.
    Coverage implication

    Ordering and Documentation Requirements

    Documentation Required

    Ordering requirements — document clinical rationale and use valid codes (restrictions may exist elsewhere)

    Provide appropriate documentation to support orders and ensure valid code combinations; this policy notes ordering-provider restrictions may apply (e.g., primary care versus specialist) in other sections, but specifics are not present in this excerpt.

    • Include clinical rationale and supporting documentation with orders as requested during claim review.
    • If plan or product documents impose ordering-provider restrictions, follow those rules when ordering and billing.
    Note

    Ordering requirements — clinical guidance cited; no provider-type limits shown here

    No ordering-provider restrictions are specified in this excerpt; the policy cites CDC, USPSTF and FDA guidance for clinical context and recommended screening intervals.

    • Refer to cited clinical guidance (CDC, USPSTF, FDA) for screening recommendations referenced by the policy.
    • Confirm any provider-type ordering limits in applicable Plan or contract documents.

    Policy Changes and Revision History

    2026-05-15approval

    Policy approved; document updated with literature review and changes including moving prenatal STI screening into this policy, adding treponemal Ig testing exclusion for current/past syphilis, and multiple test-method clarifications and code additions/removals.

    2026-04-24code_update

    Added code 87494 (recorded in policy history as an addition on 04/24/2026).

    2026-01-03terminology_clarification
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyDiagnostic Testing of Common Sexually Transmitted Infections
    Policy CodePolicy RPLAB051
    Change TypeMaterial revisions and code updates (coverage moved from CPCPLAB014exclusions clarified)
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and valid code combinations; claims may require additional documentation upon request.
    SourceLink
    On This Page
    Coverage and Reimbursement CriteriaCovered Indications and Organism-Specific RulesProcedure Codes and Coding ReferencesScreening Frequency and Follow-up LimitsTests and Methods Not ReimbursableProvider Documentation, Billing, and Ordering RequirementsDefinitions and Testing TerminologyOrdering and Documentation RequirementsPolicy Changes and Revision History
  1. HSV: Qualitative NAAT for HSV-1 or HSV-2 may be reimbursable for individuals with active genital ulcers or mucocutaneous lesions; type-specific HSV-2 (gG2) antibody testing may be reimbursable in defined diagnostic circumstances.
  2. Trichomonas qualitative NAAT: annual screening reimbursable for asymptomatic individuals in high-risk groups and for persons with HIV infection.once per year
  3. Mycoplasma genitalium screening for asymptomatic individuals using NAAT is NOT reimbursable.
  4. PrEP-related screening: Qualitative NAAT for gonorrhea/chlamydia and syphilis blood testing reimbursable every 3 months for MSM and every 6 months for sexually active individuals while initiating or receiving PrEP.every 3 months (MSM) / every 6 months (sexually active)
  5. HPV: HR-HPV testing reimbursable for cancer diagnosis/assessment (IHC p16 or NAAT for HR-HPV); HPV testing for routine asymptomatic STI panels is not reimbursable.
  6. HSV: NAAT for active lesions; type-specific serology for select diagnostic scenarios; non-specific antibody or antigen testing not reimbursable.
  7. Mycoplasma genitalium: NAAT reimbursable for symptomatic diagnosis; NAAT for antimicrobial resistance (macrolide) is not reimbursable.
  8. Qualitative NAAT screening for gonorrhea and chlamydia reimbursable: once every 3 months for MSM while initiating or receiving PrEP.every 3 months (MSM)
  9. Qualitative NAAT screening for gonorrhea and chlamydia reimbursable: once every 6 months for sexually active individuals while initiating or receiving PrEP.every 6 months (sexually active)
  10. Syphilis blood testing reimbursable for PrEP users: once every 3 months for MSM and once every 6 months for sexually active individuals.every 3 months (MSM) / every 6 months (sexually active)
  11. Prior to initiating PrEP, triple hepatitis B panel (HBsAg, anti-HBs, total anti-HBc) may be reimbursable per referenced policy; see Hepatitis testing policy for details.
  12. HCPCS citation yearCenters for Medicare & Medicaid Services HCPCS Level II reference cited 2026.
    inv-09: Qualitative NAAT specification
    Qualitative NAAT clarificationPolicy language was revised to add the word 'qualitative' to multiple NAAT items (e.g., chlamydia, gonorrhea, T. vaginalis, HSV) to indicate detection-focused NAATs are reimbursable per listed indications.
    Affected itemsClarification applied to several reimbursement statements (noted in policy history as additions to #4, #7, #12, #15 and elsewhere).
    Implication for coverageOnly qualitative (detection) NAATs are described as potentially reimbursable under the specified indications; quantitative or direct-probe/quantitative NAATs are listed as not reimbursable where specified.
    Specified for HIV-positive men or men who have sex with men (MSM); aligns with PrEP monitoring guidance in the policy history and Reimbursement Information.
    Related testsApplies to syphilis serology and to NAAT screening intervals where indicated for MSM/HIV-positive MSM.
    inv-25: NAAT screening for gonorrhea and chlamydia and syphilis blood tests for sexually active individuals on PrEP
    Semiannual PrEP screening (sexually active individuals)Once every six months for NAAT screening for gonorrhea and chlamydia and syphilis blood tests for sexually active individuals on PrEP.
    PrEP initiation and monitoringApplies both prior to beginning and while on a PrEP regimen as stated in policy #22 revisions.
    PopulationSexually active individuals (non-MSM) receiving PrEP where policy indicates every six-month screening intervals.
    inv-27: Qualitative NAAT for gonorrhea and chlamydia; syphilis blood testing
    MSM screening intervalQualitative NAAT for gonorrhea and chlamydia; syphilis blood testing: once every three months for MSM.
    Sexually active individuals intervalQualitative NAAT for gonorrhea and chlamydia; syphilis blood testing: once every six months for sexually active individuals (per PrEP guidance).
    Test typePolicy specifies qualitative NAATs for gonorrhea and chlamydia when reimbursable under these screening intervals.
    inv-28: Trichomonas and other follow-up NAAT guidance
    Follow-up testing for TrichomonasFollow-up NAAT testing a minimum of three months after initial trichomoniasis diagnosis.
    Symptomatic testingQualitative NAAT for T. vaginalis may be reimbursable for symptomatic individuals; rapid enzyme immunoassay is not reimbursable.
    Annual screeningAnnual screening for asymptomatic individuals in high-risk groups and for individuals with HIV is described as reimbursable.
    inv-26: (placeholder frequency item with no explicit label)
    Frequency placeholderPolicy contains an entry for frequency limits without an explicit label in this document segment; refer to full policy frequency tables for specifics.
    ActionSee the policy's Frequency Limits and Reimbursement Information sections for the complete specification tied to procedure codes.
    Codes referenceAssociated procedure codes and coding notes appear in the Procedure Codes section of the policy.
  13. Chlamydia: 86631, 86632, 87490-87492, 87494
  14. Gonorrhea: 87590-87592, 87494
  15. Herpes/HSV: 86694-86696, 87528-87530
  16. HPV: 87623-87626
  17. Trichomonas: 87660, 87661
  18. Mycoplasma genitalium: 87563
  19. Multi-organism NAATs: e.g., 87494
  20. Prior Authorization

    PrEP pre-initiation HBV testing and PrEP STI screening intervals

    Before initiating a PrEP regimen, triple-panel hepatitis B testing (HBsAg, anti-HBs, total anti-HBc) may be reimbursable; ongoing PrEP-related STI screening intervals are specified for qualitative NAATs and syphilis blood tests.

    • Pre-initiation hepatitis B panel: HBsAg, anti-HBs, total anti-HBc (may be reimbursable).
    • Qualitative NAAT screening for gonorrhea and chlamydia: once every 3 months for MSM; once every 6 months for sexually active individuals.
    • Blood testing to screen for syphilis: once every 3 months for MSM; once every 6 months for sexually active individuals.
    Documentation Required

    Ordering and documentation requirements for test orders

    When ordering and billing STI tests, submit appropriate documentation and valid code combinations; ordering-provider restrictions are not specified in this excerpt but the policy notes that provider documentation and valid coding are required.

    • Ensure claims use valid HIPAA-approved code sets and adhere to industry coding guidelines (CPT, HCPCS, ICD-10).
    • Be prepared to provide additional documentation upon request to support medical necessity and correct coding.
    Note

    No explicit ordering-provider restrictions in this excerpt

    This policy excerpt does not specify limitations on which provider types may order tests; clinical guidance references (CDC, USPSTF, FDA and others) are cited for context in the policy.

    • No ordering-provider restrictions are specified in the provided policy text.
    • Clinical guidance sources are cited for recommended screening intervals and indications.
    Note

    Screening interval guidance and note on prenatal screening

    Follow recommended screening intervals referenced by the policy: qualitative NAATs and syphilis blood testing frequency guidance is included for MSM and sexually active individuals, and prenatal screening was moved into this policy.

    • Qualitative NAAT for gonorrhea and chlamydia; syphilis blood testing: every 3 months for MSM and every 6 months for sexually active individuals.
    • Prenatal STI screening items were transferred into this policy (policy history note).
    Policy explicitly distinguishes qualitative NAATs as potentially reimbursable under specified indications; quantitative NAATs and direct-probe/quantitative methods may be listed as not reimbursable where stated.
    Example organismsQualitative NAATs are described for chlamydia, gonorrhea, Trichomonas vaginalis, M. genitalium (when symptomatic), and HSV NAAT for lesion testing.
    inv-15: Procedure code types — CPT, HCPCS, and proprietary U-codes corresponding to laboratory tests for STIs
    Procedure code typesPolicy lists CPT codes, HCPCS Level II entries, and proprietary U-codes corresponding to laboratory STI tests (examples include 86592, 87491-87494, 87590-87592, 87623-87626, 0064U, 0065U, 0484U).
    UsesCodes represent syphilis serology (treponemal and non-treponemal), NAATs for chlamydia/gonorrhea/trichomonas, HSV molecular assays, HPV typing, and Mycoplasma genitalium NAATs.
    Reference noteFull procedure code list and descriptions are provided in the Procedure Codes section of the policy and are accompanied by CPT/HCPCS copyright citations.
    inv-16: qualitative NAAT (duplicate reference)
    Qualitative NAAT (reiteration)Policy text repeatedly clarifies that qualifying NAATs are 'qualitative' (detection-focused) for reimbursable indications across multiple organisms.
    Coverage boundaryWhere 'qualitative NAAT' is specified, quantitative or direct-probe/quantitative NAATs are treated differently and may be non-reimbursable per policy statements.
    ExamplesChlamydia, gonorrhea, and Trichomonas NAATs are referenced as qualitative NAATs in reimbursable scenarios.
    inv-17: symptomatic indication — distinctions between symptomatic and asymptomatic testing (e.g., M. genitalium)
    Symptomatic vs asymptomatic distinctionThe policy differentiates symptomatic testing (often reimbursable) from asymptomatic screening (restricted to defined high-risk groups); e.g., M. genitalium NAAT may be reimbursable when symptomatic but not for asymptomatic screening.
    ExamplesQualitative NAAT for HSV is reimbursable for individuals with active genital ulcers or mucocutaneous lesions; herpes serologic screening in asymptomatic individuals is not reimbursable.
    Implication for orderingProviders should document symptomatic indications when ordering NAATs that are reimbursable only for symptomatic patients (policy notes and Notes referenced).
    Note

    Ordering requirements — recommended intervals for MSM and sexually active individuals; prenatal screening moved here

    The policy explicitly references screening intervals for MSM and sexually active individuals (quarterly for MSM, semiannually for sexually active individuals) and indicates prenatal screening has been incorporated into this policy from the prior prenatal testing policy.

    • Screening intervals: Qualitative NAAT for gonorrhea/chlamydia and syphilis blood testing — every 3 months for MSM; every 6 months for sexually active individuals.
    • Prenatal screening provisions were moved into this policy (see policy history).

    Added the term 'qualitative' to NAAT references in several items and clarified NAAT mentions and reimbursement situations for Trichomonas and other items during a literature review update.

    2025-04-15code_update

    Added code 87626 and revised PrEP-related screening and pre-transplant testing statements; multiple code removals and reference updates recorded.

    2023-11-01coverage_change

    Clarified reimbursement for Mycoplasma genitalium NAAT (reimbursable when symptomatic; not reimbursable for asymptomatic screening), added Trichomonas vaginalis and M. genitalium to certain sections, and added multiple U-codes while removing others.

    2022-11-01policy_creationLatest

    Original policy created (new policy) establishing diagnostic testing reimbursement rules for common STIs.